Akèy › Kansè selil dendritik plasmacytoïd blastik
Etid klinik pou Kansè selil dendritik plasmacytoïd blastik ap rekrite nan Etazini
8 etid pou Kansè selil dendritik plasmacytoïd blastik ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
Pa eta
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Ap rekriteFaz 2
Laj 18 ak plis · Tout sèks · Mizajou Sep 14, 2026 · NCT04216524Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Ap rekriteFaz 2
6 Months – 65 Years · Tout sèks · Mizajou Jul 22, 2026 · NCT06013423SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Jun 17, 2026 · NCT03113643Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry
Ap rekriteEtid obsèvasyon
Tout laj · Tout sèks · Mizajou Jun 5, 2026 · NCT05430971CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)
Ap rekriteFaz 1
Jiska laj 21 · Tout sèks · Mizajou May 19, 2026 · NCT04318678HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Ap rekriteFaz 1
Jiska laj 80 · Tout sèks · Mizajou May 18, 2026 · NCT03326921Q702 for the Treatment of Patients With Hematologic Malignancies
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Oct 10, 2025 · NCT06712810Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
Ap rekriteFaz 1
Laj 1 a 21 · Tout sèks · Mizajou Dec 6, 2024 · NCT05476770Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.